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AbstrAct
Objectives To evaluate the 12-month costs and quality-
adjusted life years (QALYs) gained to the Italian National 
Health Service of facilitated access to a website for 
hazardous drinkers compared with a standard face-to-face 
brief intervention (BI).
Design Randomised 1:1 non-inferiority trial.
setting Practices of 58 general practitioners (GPs) in Italy.
Participants Of 9080 patients (>18 years old) approached 
to take part in the trial, 4529 (49·9%) logged on to the 
website and 3841 (84.8%) undertook online screening for 
hazardous drinking. 822 (21.4%) screened positive and 
763 (19.9%) were recruited to the trial.
Interventions Patients were randomised to receive either 
a face-to-face BI or access via a brochure from their GP to 
an alcohol reduction website (facilitated access).
Primary and secondary outcome measures The 
primary outcome is the cost per QALY gained of facilitated 
access compared with face-to-face. A secondary analysis 
includes total costs and benefits per 100 patients, 
including number of hazardous drinkers prevented at 12 
months.
results The average time required for the face-to-face BI 
was 8 min (95% CI 7.5 min to 8.6 min). Given the maximum 
time taken for facilitated access of 5 min, face-to-face is 
an additional 3 min: equivalent to having time for another 
GP appointment for every three patients referred to the 
website. Complete case analysis adjusting for baseline the 
difference in QALYs for facilitated access is 0.002 QALYs 
per patient (95% CI −0.007 to 0.011).
conclusions Facilitated access to a website to reduce 
hazardous drinking costs less than a face-to-face BI 
given by a GP with no worse outcomes. The lower cost of 
facilitated access, particularly in regards to investment 
of time, may facilitate the increase in provision of BIs for 
hazardous drinking.
trial registration number NCT01638338;Post-results.
IntrODuctIOn
Consumption of alcohol is a risk factor for 
premature mortality,1 with growing evidence 
of the significant negative health impact of 
alcohol consumption, including increased 
risk of cancer.2 The WHO has identified the 
European region as having the highest rates 
of alcohol-related ill health across the globe.2 
Brief interventions (BIs) have been found to 
be effective in reducing alcohol consump-
tion in primary care populations3 leading 
to recommendations for their implementa-
tion in primary care, including in the Italian 
National Guidelines.4 Delivering a face-to-face 
standard BI alongside screening the Italian 
population for hazardous drinking is poten-
tially cost-effective to the Italian National 
Health Service (INHS), with the potential 
to prevent 7200 alcohol-related deaths over 
30 years and 91 700 alcohol-related hospi-
talisations.5 Despite strong evidence of their 
potential benefit, the implementation of 
BIs in primary care across Europe has been 
limited.6 This may be due to the signifi-
cant upfront investment required to deliver 
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Research
strengths and limitations of this study
 ► The cost-effectiveness analysis uses individual 
patient data to evaluate the short-term costs and 
benefits of a way to increase the implementation 
of brief interventions (BI) for hazardous and harmful 
drinkers in primary care.
 ► Follow-up rates exceeded 90% at 3 months and 
80% at 12 months.
 ► Limited data were collected as part of the trial on 
time taken in standard Italian GP appointments and 
cost of a GP in Italy, so assumptions based on data 
from the literature were required.
 ► The results were extrapolated to the English National 
Health Services, hence caution should be exercised 
interpreting these findings given differences 
between the Italian and English NHS.
 ► The results of the analysis are dependent on 
assumptions made regarding the number of patients 
who receive a face-to-face BI or the number of 
patients who access the website.
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face-to-face BIs in the form of GP or other primary care 
staff time, of which there is finite availability.
As a result, an alternative approach may be required to 
deliver BIs in primary care, one that is less of a burden 
on clinician time and is easier to implement. Facilitated 
access, where a clinician directs patients to a website for 
alcohol reduction, has the potential to provide similar 
benefits to a face-to-face BI but potentially with a lower 
upfront investment in time and hence cost. Although 
there is evidence regarding the potential impact of BIs 
on reducing alcohol consumption and hence anticipated 
long-term health benefits, there is less evidence for their 
impact on short-term costs and health-related quality of, 
particularly in, an Italian primary healthcare setting.5 This 
information is required to identify strategies to improve 
the implementation of BIs in the INHS.
The aim of this health economic evaluation is to eval-
uate the short-term cost savings to the INHS of facilitated 
access to a website for hazardous and harmful drinkers 
compared with a standard face-to-face BI over 12 months. 
Hazardous drinkers are defined as people with an alcohol 
consumption level that is potentially detrimental to their 
health and is measured using the Alcohol Use Disorders 
Identification Test (AUDIT).7 These will be reported 
alongside potential benefits. Face-to-face BI for hazardous 
drinking has been recommended for widespread imple-
mentation in the English National Health System (NHS), 
but that evidence suggests that this has not happened.6 
We have therefore included a secondary analysis of the 
potential cost savings to the English NHS of facilitated 
access to a website to provide additional information to 
NHS policy-makers.
MethODs
eFAr trial
Effectiveness of primary care based Facilitated Access to 
alcohol Reduction website - a non-inferiority random-
ized controlled trial-Friuli Venezia Giulia (EFAR-FVG) is 
a randomised 1:1 trial, with the primary aim of testing 
for non-inferiority of a face-to-face BI for hazardous 
and harmful drinkers delivered by a GP (face-to-face 
BI) compared with facilitated access to an interactive 
website for reducing hazardous and harmful drinking 
(facilitated access). GPs from the region of Northern 
Italy, Friuli-Venezia, were recruited via the official 
register for the region. Patients aged ≥18 years and who 
did not meet any of the exclusion criteria for the trial 
were recruited to the trial by being given a trial brochure 
and encouraged by their GP to access a healthy lifestyle 
website. Patients who accessed the website were asked 
to complete the short Alcohol Use Disorders Identifica-
tion Test (AUDIT-C).8 9 The AUDIT-C is comprises three 
questions to identify probable hazardous or harmful 
drinking, with a lower threshold score of 5 for men and 
4 for women. Patients scoring at the threshold and above 
on the AUDIT-C were advised of their risk via a person-
alised message from their GP and advised to enter the 
study. Following consent to the study, patients completed 
baseline questionnaires and were randomised to face-to-
face BI or facilitated access (the GP gives the patient a 
leaflet that directs them to the website) to a version of 
the Down Your Drink Website (www. downyourdrink. org. 
uk) adapted for an Italian audience. Further details of 
the EFAR-FVG trial10 11 and Down Your Drink website12 
can be found elsewhere.
costs
The aim of this analysis is to assess the short-term 
resource impact of facilitated access to a website. There 
is unlikely to be a significant immediate health benefit to 
patients as a result of reductions in alcohol consumption 
given the long-term impact and health risk of hazardous 
and harmful drinking. As a result the only resource use 
collected as part of the trial was time spent by GPs deliv-
ering the standard face-to-face BI as this is likely to be the 
main source of cost savings. GPs indicated if the face-to-
face BI took <5 min, 5–10 min or >10 min. The cost per 
minute of a GP appointment was then multiplied by 5, 10 
or 15 min for each patient to obtain the cost per patient 
of the face-to-face BI. The time and cost of screening was 
not included given that it was assumed to be the same in 
both groups. GPs were also asked to report how long it 
took them to refer patients to the website.
The cost of a GP appointment was taken from the 
Italian study published by Gerzeli et al13 and was esti-
mated at €11 an appointment for 2010 costs. No health-
care cost inflation index for Italy could be located, so 
instead the English healthcare cost inflation index was 
applied to bring the cost to 2015/2016 values14 at €12 
an appointment. Assuming an average appointment 
length of 9 min,15 this equates to a cost per minute of 
€1.27. The primary analysis for costs is from the Italian 
healthcare perspective. A secondary analysis evaluating 
the potential cost savings for the English NHS costs has 
also been conducted to provide hypothetical informa-
tion on the probability of the intervention is cost-effec-
tive in England. As reported in Hobbs et al15 study of 
101.8 million GP consultations carried out in English GPs, 
the average duration of a GP appointment in England is 
9.2 min at a cost of £31.14 The significantly higher cost 
of GP time in the English NHS compared with INHS is 
likely to be a result of higher salaries and overhead costs 
in the English NHS.
All GPs attended a 1-day training session for the delivery 
of a face-to-face BI for hazardous and harmful drinking 
using motivational interviewing, with an average cost per 
GP participant of €51 for the cost of trainers, resources 
and room hire. The cost of an honorarium and travel 
costs for experts leading the training (€10 971), and cost 
of the GP’s time attending the training (at €533 per GP 
per day) was also included in the cost of training.
The cost of adapting the website was collected as part 
of the trial at a total cost of €35 000. GPs were asked to 
familiarise themselves with use of the website prior to 
start of the trial at a cost per GP of €76.
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Quality-adjusted life years
Quality-adjusted life years (QALYs) represent a measure 
of mortality and morbidity over time, anchored at 1 for 
perfect health and 0 for death, with 1 year spent in perfect 
health equal to 1 QALY. They are used to assist health-
care policy-makers with decisions about the implementa-
tion of new interventions in healthcare in an equitable 
and standardised way. The cost of the new intervention 
minus current practice is divided by the additional QALYs 
generated by the new intervention to calculate the cost 
per QALY gained, with a lower mean cost per QALY being 
preferable. The new intervention might also dominate 
current practice by resulting in more QALYs for a lower 
average cost per patient. The EuroQol EQ-5D16 and its 
associated preference-based tariff17 is the most common 
way to calculate QALYs in most developed countries.
Euroqol EQ-5D 5 level (EQ-5D-5L)18 was adminis-
tered to all patients in the trial to complete at baseline, 3 
months and 12 months. Patients were asked to complete 
questionnaires online in the first instance, but for some 
patients questionnaires were completed over the phone 
following multiple attempts to contact the patient to 
complete the questionnaire online. The 5-level version of 
the EQ-5D was chosen given recent evidence of a reduced 
ceiling effect compared with the 3 level.19 Time trade-off 
values for the EQ-5D-5L were used to calculate patient-
level utility tariffs. As no Italian weights are currently 
available in the cross-walk or time trade-off value sets for 
the EQ-5D-5L, the time trade-off algorithm for the UK 
was applied.20
Patient-level QALYs were calculated from baseline, 
3-month and 12-month patient-level utility scores, 
adjusting for timing of follow-ups to calculate the area 
under the curve. Adjustments were not patient specific 
and were counted specifically as 3 months and 12 months 
regardless of when the patient actually completed the 
questionnaire so as not to introduce bias from delayed 
responses. As responses at all three time points are 
required to calculate QALYs, values reported are for 
complete case analysis (patients who have complete 
EQ-5D-5L responses for all three time points). The mean 
QALYs per patient reported have been adjusted for base-
line EQ-5D-5L utility values using linear regression anal-
ysis and including a coefficient for randomisation.21 CIs 
are from 1000 bootstrap replications.
cases of hazardous or harmful drinking prevented
As hazardous drinkers also include a generally healthy 
population, with potential QALY losses occurring in 
the far future as a result of future chronic alcohol-re-
lated health problems, the EQ-5D has been found to be 
insensitive to changes in hazardous drinking at the point 
of behaviour change for risk reduction.22 As a result, 
additional analyses of costs versus cases of hazardous 
or harmful drinking prevented have been included. 
Patients completed the 10 question version of the AUDIT 
(AUDIT-10) at baseline, 3 months and 12 months, with 
hazardous or harmful drinking defined as a score ≥8. 
Cases of hazardous or harmful drinking prevented at 
12 months have been calculated using the data from 
the main paper for the trial using AUDIT-10 data at 12 
months.11 This was converted to cases prevented per 1000 
patients by calculating the percentage of patients that 
are hazardous or harmful drinkers at 12 months in the 
face-to-face BI, changing this to a rate per 1000 patient 
years and applying the OR reported in the main clinical 
paper11 for 12 months.
sensitivity analysis: missing data
It was assumed that data at follow-up time points were 
missing at random. Additional analyses have been 
conducted using alternative ways to account for missing 
data in QALYs. This includes an incomplete case anal-
ysis using all data collected, not just complete cases, 
to calculate QALYs and calculating QALYs imputing 
missing data using chained equations as recommended 
in Hunter et al.23
cost-effectiveness plane and cost-effectiveness acceptability 
curve
Results from the bootstrapped, complete case, QALYs 
were used to generate the cost-effectiveness plane (CEP) 
and cost-effectiveness acceptability curve (CEAC).
To represent the uncertainty in costs the average dura-
tion of the appointment was calculated using the propor-
tion of patients who had appointments of different 
lengths and the Dirichlet process.24 The cost was varied 
using a random number generated in Excel and the 
gamma distribution assuming that the SE is equal to the 
mean cost of an appointment (€12 for IHNS and £31 
in the UK). An average cost per appointment was then 
generated for each of the 1000 simulated iterations and 
for Italian and UK costs.
The CEAC is calculated using the formula (β1)WTP−
(C1−C2), where β1 is the beta coefficient for the treatment 
effect from one of the iterations of the bootstrapped 
linear regressions adjusting for baseline EQ-5D-5L utility 
scores, WTP is the willingness to pay for a QALY gained, 
C1 is the average cost per patient of facilitated access and 
C2 is cost of the average cost per patient of the face-to-face 
BI. The probability that facilitated access is cost-effective 
compared with the face-to-face BI for a given WTP for a 
QALY is based on the proportion of times the formula 
is positive from the 1000 bootstrap iterations combined 
with the 1000 simulated iterations.
No discount rate was applied to the analysis given the 
12-month time horizon.
hypothesis testing
Given the hypothesis of non-inferiority between the two 
groups as the primary analysis for the trial, it was assumed 
that there would be no difference in QALYs or cases of 
hazardous or harmful drinking between the two groups. 
Instead the analysis focuses on the potential benefit per 
1000 patients with facilitated access to the alcohol reduc-
tion website compared with a brief face-to-face BI. As no 
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Figure 1 Consort diagram. Patient progress through trial for the primary outcome.
information of the average GP appointment duration in 
Italy is available, it has been assumed that the average 
appointment duration in Italy is similar to that of the 
English NHS of 9 min.
results
Patient numbers and loss to follow-up for the trial are 
reported in figure 1. Further patient demographics can 
be found in the main trial findings paper11.
costs
Of the 416 patients allocated to the face to face BI group, 
304 (73%) received the BI from their GP. Information on 
the duration of each BI was recorded by the GPs using 
a questionnaire. For 171 patients (56.3%), the BI took 
<5 min, 5–10 min for 87 patients (28.6%) and >10 min for 
46 patients (15.1%). The average time required for the 
face-to-face BI is 8 min (95% CI 7.5 min to 8.6 min). The 
amount of time spent facilitating access to the website was 
<5 min. Based on this, we made the conservative estimate 
that facilitated access required 5 min of a GP’s time. The 
difference of 3 min between the two groups is equivalent 
to having time for another appointment for every three 
patients referred to the website.
The average cost per patient of a face-to-face BI, 
including patients randomised to face-to-face BI but who 
did not receive the face-to-face appointment was €10,16 
per patient (95% CI €9,53 to €10,92). If patients who 
did not receive the face-to-face BI are excluded from the 
analysis, the average cost is €11,10 per patient (95% CI 
€10,52 to €11,69).
The average cost per GP of training to deliver the face-
to-face BI was €774. The cost per patient of training for 
face-to-face BI is dependent on how many patients the GP 
delivers a face-to-face BI to. Assuming that GPs could have 
provided a face-to-face BI to patients in either group, the 
total number of interventions they could have provided 
was 763, or 13 patients per GP, resulting in an average cost 
per patient of €60 for training for face-to-face BI.
The total cost of website development and piloting was 
€47 408, including the cost of GPs familiarising them-
selves with the website. Assuming 763 patients received 
facilitated access, the cost per patient of the website is 
€62,13. Each patient was also given a leaflet from the GP 
directing them to the website at a total cost per patient of 
€0,51. In the most conservative scenario (lowest possible 
cost difference between the two groups) of €70 per 
patient for face-to-face BI (€60 for training and €10,16 
for the GP time to deliver the BI) and facilitated access 
costs €68 per patient (5 min for facilitated access, the 
cost of the leaflet and an additional cost per patient of 
updating the website of €62), facilitated access costs €2 
less per patient compared with face-to-face BI.
In the least conservative estimate (highest possible cost 
difference between the two groups), we assume that the 
cost of the website approaches zero given that there is no 
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Table 1 Mean utility scores and QALYs for face-to-face and facilitated access
Face-to-face Facilitated access
Baseline 3 months 12 months QALYs Baseline 3 months 12 months QALYs
N 415 381 335 331 346 317 285 275
Mean 0.914 0.942 0.938 0.937 0.913 0.942 0.938 0.937
SE 0.004 0.004 0.004 0.004 0.005 0.004 0.005 0.004
95% CI—lower 0.905 0.934 0.93 0.929 0.903 0.934 0.929 0.929
95% CI—upper 0.923 0.949 0.948 0.944 0.923 0.95 0.948 0.945
QALYs, quality-adjusted life years.
Table 2 Difference in health utility of facilitated access 
compared with face-to-face BI at 3 months and 12 months 
and adjusted difference in QALYs
Analysis Estimate
Lower 
95% CI
Upper 
95% CI p Value
Complete case
3-month EQ-5D-5L 0.003 −0.010 0.013 0.658
12-month EQ5D 5 L −0.0003 −0.013 0.012 0.960
QALYS (adjusted) 0.002 −0.007 0.01 0.622
Incomplete case
3-month EQ-5D-5L 0.0006 −0.011 0.012 0.914
12-month EQ-5D-5L 0.0004 −0.013 0.013 0.955
QALYS (from means) 0.0003
Multiple imputation
3-month EQ-5D-5L 0.0006 −0.010 0.012 0.913
12-month EQ-5D-5L 0.0005 −0.012 0.013 0.935
QALYS (adjusted) 0.0006 −0.009 0.01 0.901
EQ-5D-5L, Euroqol EQ-5D 5 level; QALYs, quality-adjusted life 
years.
upper limit to the number of patients who could feasibly 
access the website. Instead the only costs for facilitated 
access are the cost of the leaflet (€0,51 per patient), GP 
time referring patients to the website (5 min at a cost of 
€6,35 per patient) and time spent familiarising them-
selves with the website (€5,86). In the least conservative 
estimate we assume that the cost per patient for face-to-
face BI is €71 (€60 for training and €11,10 for the GP 
time to deliver the BI) and facilitated access costs €13 per 
patient (5 min for facilitated access and an additional cost 
of the leaflet and GPs time familiarise themselves with the 
website of €6,37) facilitated access results in a cost saving 
of €58 per patient compared with face-to-face BI.
utility scores and QAlYs
The results for mean complete case analysis for utility 
scores and QALYs are reported in table 1.
There was no significant difference in QALYs between 
facilitated access to the website and the face-to-face BI. 
Complete case analysis and adjusting for baseline the 
difference in QALYs for facilitated access minus face-to-
face BI was 0.002 per patient (95% CI −0.007 to 0.011). At 
a willingness to pay (WTP) of €25 000 per QALY gained, 
as recommended by the INHS,25 facilitated access could 
cost an additional €50 per patient on average compared 
with face-to-face BI and be considered cost-effective. At 
the lower end of the CI where facilitated access results 
in a QALY decrement of −0.007 QALYs over 1 year, facil-
itated access would need to save €175 per patient to be 
cost-effective. The difference in utility scores and QALYs 
is described in table 2. Based on the results of the multiple 
imputation analysis, facilitated access can cost an addi-
tional €15 compared with face-to-face BI and be consid-
ered cost-effective (95% CI −€225 to €250).
cost-effectiveness plane and cost-effectiveness acceptability 
curve
Results of the CEP and CEAC are reported in figure 2. 
There is a 70% probability that the intervention is cost-ef-
fective from an INHS cost perspective when all relevant 
costs are included (intervention delivery, training and 
website development) at a WTP for a QALY of €25 
000, and an 84% probability if only the cost of training 
(excluding website development costs) are included. 
There is a 75% probability that the website is cost-effec-
tive compared with face-to-face BI if English NHS costs 
are used and intervention costs only are included, at a 
WTP for a QALY of £25 000.
benefits per 1000 patients referred
The results from the AUDIT analysis are reported in 
the clinical paper.11 At 12 months, there was no signif-
icant difference between two groups in the number 
of hazardous or harmful drinkers with an OR of 0.94 
(95% CI 1.432 to 0.621). At 12 months, of the patients 
randomised to face-to-face BI, 26.3% were hazardous 
or harmful drinkers (AUDIT-10 ≥8) or 263 patients per 
1000. Change this to a rate of 263 patients per 1000 
patient years and applying an OR of 0.94, 18 patients 
per 1000 patient years are prevented from hazardous 
or harmful drinking if they were given facilitated access 
instead of a face-to-face BI. Facilitated access compared 
with the face-to-face BI also results in time for an addi-
tional 333 appointments.
Question 10 in the AUDIT-10 asks patients if a health-
care professional has recommended that they reduce their 
drinking. Potentially as a result of the nature of the inter-
vention (a GP discussing their drinking with them) this was 
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Figure 2 (A) Cost effectiveness acceptability plane (Italian costs only). (B) Cost-effectiveness acceptability plane (Italian and 
UK costs). Blue, INHS GP time only; orange, English NHS; grey, INHS training and website; yellow, INHS training only. GP, 
general practitioners; INHS, Italian National Health Service; NHS, National Health Service.
the question most frequently with a score >0 compared with 
other questions on the AUDIT. In the face-to-face group, 
40% of patients answered >0 to question 10% and 31% in 
the intervention group at 12 months. If this is taken into 
account and a lower threshold of 7 for hazardous drinking 
applied, 16% of patients fall above the threshold for risky 
drinking in the face-to-face group and 18% in the facili-
tated access group with an OR of 1.9 (95% CI 1 to 3.7). This 
equates to 158 additional hazardous or harmful drinkers 
per 1000 patient years for facilitated access compared with 
face-to-face BI.
DIscussIOn
Our findings indicate that in the INHS system, the 
chance that facilitated access to a website to reduce 
hazardous drinking is cost-effective compared with a face-
to-face BI delivered by a GP is between 70% and 84%. 
However, these numbers are dependent on assumptions 
made about the number of patients given facilitated 
access versus those given a face-to-face BI given the high 
up-front costs of website modification or training, respec-
tively. The costs per patient decrease as more patients 
access each treatment.
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Although no data on the long-term benefits were 
included as part of this trial, other modelling studies in 
Italy have looked at the potential long-term benefits of 
BIs. Angus et al5 modelled screening of the adult Italian 
population and providing a standard BI for those iden-
tified as hazardous drinkers over 10 years. They esti-
mated that 32% of population receive the intervention 
at a cost of €411 million, with a potential cost saving of 
€370 million and a QALY gain of 75 200. This translates 
to an incremental cost-effectiveness ratio (ICER) of 550 
per QALY gained. Given that facilitated access to a website 
costs significantly less than the standard BI across a whole 
population, it is likely that population-level screening for 
hazardous drinking and a facilitated access to a website 
is potentially cost saving. The lower cost in terms of time 
required of facilitated access compared with face-to-face 
may also increase the probability that BIs are imple-
mented in the INHS.
Given the low level of implementation in the English 
NHS and the higher cost per hour of English GPs, if 
the findings from the Italian study were equivalent in 
England, there would be an even greater probability that 
facilitated access is cost-effective compared with a face-
to-face BI. This result though should be interpreted with 
caution and points to the need for additional research in 
this area in England.
strengths and weaknesses
Limited resource use data were collected as part of the 
trial. In particular there were no data on what impact 
access to the website had on follow-up GP appoint-
ments. If patients had concerns about the information 
they accessed on the website, it is the possible that they 
went to see their GP for additional advice, representing 
an additional cost that was not included in this analysis. 
Conversely, any cost savings as a result of prevention of 
alcohol related admissions were not captured as part of 
this study. If the wider costs to society beyond healthcare 
are considered, the cost to the economy of productivity 
losses as a result of alcohol-related days off work and 
loss of productivity were also not included. A trial of an 
online BI implemented in the work place found that the 
intervention group were less likely to have sick leave and 
for less days in total, although not significantly so.26 This 
though represents an important consideration for inclu-
sion for trials in this area and population group.
Obtaining high-quality information on the cost of 
GP time in Italy was challenging, with availability only 
of limited information on GP time and costs and no 
published national costs.5 As a result, there is limited 
information to use for costing. However, the two sources 
used to cost GP time resulted in a similar value per 
minute of GP time suggesting consistency in the way GP 
time is costed in Italy. The lack of availability of an Italian 
tariff for the EQ-5D-5L is also a limitation of this study. 
An Italian tariff developed for the 3-level version of the 
EQ-5D found that Italian valuations were higher, partic-
ularly for more severe health states.27 Further research 
would be required to evaluate the implications for studies 
similar to these.
We have used data from the English NHS to estimate 
the potential cost-effectiveness of the intervention in an 
English primary care population. Previous trials of online 
interventions for reducing hazardous drinking in the UK 
have found it challenging to achieve high enough rates of 
follow-up to enable reliable measurement of effectiveness 
and cost-effectiveness.22 It is not possible to be sure that 
there would be a similar level of effectiveness of facilitated 
access compared with face-to-face BI in England, but the 
cost savings are likely to be similar to those projected here 
if GPs take a similar amount of time to conduct a BI.
The use of the AUDIT-10 as an outcome measure to 
measure the effectiveness of treatments for hazardous 
or harmful drinking is questionable. This is due to the 
problem with question 10 in the AUDIT which asks 
whether a healthcare professional has suggested reducing 
drinking. This is more likely to receive a positive response 
for patients screened for hazardous drinking and 
provided with any form of intervention—face-to-face BI 
or facilitated access. Advice is potentially more memo-
rable at face-to-face BI and hence the reversal of results 
when this question was removed. This is discussed further 
in the main clinical paper11.
cOnclusIOns
There is a high probability that facilitated access to a 
website to reduce alcohol consumption could deliver 
more benefits for fewer resources given that it costs less 
than the standard face-to-face BI. Additional benefits may 
also include an increase in the rates of delivery of BI via 
facilitated access given the lower time requirement for 
GPs compared with face-to-face BI.
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